novo_nordisk_flag

Novo strikes up personalised diabetes treatment deal with Glooko

pharmafile | January 16, 2017 | News story | Sales and Marketing Glooko, Novo Nordisk, ibm 

Novo Nordisk has entered into a partnership with Californian firm Glooko to develop a number of offerings to aid with a range of issues affecting patients with type 1 and 2 diabetes including treatment adherence and blood glucose management.

These offerings will be integrated within Novo’s digital health platform developed with IBM Watson Health, a “virtual doctor” born from the company’s partnership with IBM signed in 2015.

“We are excited to partner with Glooko and to take another step towards delivering digital health offerings that help people with diabetes to improve their blood glucose control,” explained Christian Kanstrup, senior vice president, Strategy, Access & Marketing at Novo Nordisk. “Working in partnerships will furthermore enhance our ability to demonstrate the real-world value of our portfolio of diabetes treatments.”

Glooko’s CEO Rick Altinger added: “Glooko’s partnership with Novo Nordisk aims to empower tens of millions of patients with digital tools to make diabetes management easier. We look forward to delivering jointly-branded capabilities that will enhance the collaboration between patient and healthcare professionals and enable us to provide joint offerings to people living with diabetes around the world.”

Matt Fellows

Related Content

CHMP recommends Novo Nordisk’s Awiqli for diabetes treatment

Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for …

Almirall licenses Novo Nordisk’s anti-IL-21 monoclonal antibody for dermatology treatment

Almirall has announced that it has entered into an exclusive license agreement with Novo Nordisk …

Novo Nordisk shares positive results from COMBINE 3 phase 3a trial

Novo Nordisk has shared topline results from the COMBINE 3 phase 3a trial of once-weeklly …

Latest content